Reuters logo
BRIEF-Eiger reports additional positive phase 2 results from multiple-ascending dose study of exendin 9-39
2017年6月12日 / 中午12点20分 / 5 个月前

BRIEF-Eiger reports additional positive phase 2 results from multiple-ascending dose study of exendin 9-39

June 12 (Reuters) - Eiger Biopharmaceuticals Inc

* Eiger reports additional positive phase 2 results from multiple-ascending dose study of exendin 9-39 in post-bariatric hypoglycemia patients at american diabetes association meeting in san diego

* Sc exendin 9-39 liquid and lyophilized formulations were well tolerated with no related adverse events

* Sc exendin 9-39 liquid and lyophilized formulations reduced postprandial hyperinsulinemic hypoglycemia

* Sc exendin 9-39 liquid and lyophilized formulations reduced hypoglycemic symptoms Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below